Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.9 USD | +3.25% | +14.10% | +505.44% |
May. 30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
May. 30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Equities
- CADL Stock
- Revisions Candel Therapeutics, Inc.